Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tecovirimat in mpox infection
NCT06156566Phase 4Recruiting
- Start
- Aug 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 4, randomised, double-blind trial in mpox comparing Tecovirimat with Placebo (2 arms). Primary endpoint: Time to complete mpox lesion resolution at 28 days. Started Aug 2024; status: recruiting.
02
Drugs
tecovirimat
03
Conditions
mpox
Beyond the preview
Go deeper on NCT06156566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06156566.